keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i
Company profile
Ticker
KROS
Exchange
Website
CEO
Jasbir S. Seehra
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Keros Therapeutics Australia, Pty Ltd • Keros Security Corporation ...
KROS stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
17 Apr 24
DEFA14A
Additional proxy soliciting materials
17 Apr 24
DEF 14A
Definitive proxy
17 Apr 24
8-K
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
14 Mar 24
8-K
March 2024 Corporate Presentation
6 Mar 24
8-K
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
5 Mar 24
8-K
Departure of Directors or Certain Officers
5 Mar 24
S-8
Registration of securities for employees
28 Feb 24
8-K
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
8-K
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
9 Jan 24
Latest ownership filings
4
Jasbir Seehra
23 Feb 24
4
Jasbir Seehra
15 Feb 24
4
Keith Regnante
15 Feb 24
4
Christopher Rovaldi
15 Feb 24
4
Simon Peter Cooper
15 Feb 24
SC 13G/A
ALKEON CAPITAL MANAGEMENT LLC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
Keith Regnante
8 Jan 24
144
Notice of proposed sale of securities
4 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 289.11 mm | 289.11 mm | 289.11 mm | 289.11 mm | 289.11 mm | 289.11 mm |
Cash burn (monthly) | 11.42 mm | (no burn) | 14.43 mm | 12.95 mm | 11.33 mm | 10.04 mm |
Cash used (since last report) | 76.28 mm | n/a | 96.39 mm | 86.55 mm | 75.68 mm | 67.09 mm |
Cash remaining | 212.83 mm | n/a | 192.71 mm | 202.55 mm | 213.42 mm | 222.02 mm |
Runway (months of cash) | 18.6 | n/a | 13.4 | 15.6 | 18.8 | 22.1 |
Institutional ownership, Q2 2023
80.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 123 |
Opened positions | 14 |
Closed positions | 20 |
Increased positions | 59 |
Reduced positions | 27 |
13F shares | Current |
---|---|
Total value | 884.36 bn |
Total shares | 28.96 mm |
Total puts | 500.00 |
Total calls | 12.90 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Pontifax Management 4 G.P. | 4.73 mm | $109.98 mm |
FMR | 4.06 mm | $163.09 bn |
BLK Blackrock | 1.74 mm | $70.09 bn |
Alkeon Capital Management | 1.68 mm | $67.36 bn |
Orbimed Advisors | 1.51 mm | $60.86 bn |
Arkin Moshe | 1.37 mm | $79.29 mm |
T. Rowe Price | 1.27 mm | $51.10 bn |
Vanguard | 1.18 mm | $47.56 bn |
Braidwell | 1.14 mm | $45.96 bn |
STT State Street | 1.02 mm | $40.82 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Feb 24 | Seehra Jasbir | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 56.18 | 125,000 | 7.02 mm | 125,000 |
13 Feb 24 | Regnante Keith | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 56.18 | 40,000 | 2.25 mm | 40,000 |
13 Feb 24 | Christopher Rovaldi | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 56.18 | 150,000 | 8.43 mm | 150,000 |
13 Feb 24 | Simon Peter Cooper | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 56.18 | 40,000 | 2.25 mm | 40,000 |
4 Jan 24 | Regnante Keith | Employee Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 16 | 40,000 | 640.00 k | 53,622 |
4 Nov 23 | Regnante Keith | Common Stock | Sell | Dispose S | No | Yes | 45.29 | 40,000 | 1.81 mm | 0 |
4 Nov 23 | Regnante Keith | Common Stock | Option exercise | Acquire M | No | Yes | 16 | 40,000 | 640.00 k | 40,000 |
News
Piper Sandler Maintains Overweight on Keros Therapeutics, Maintains $105 Price Target
27 Mar 24
Truist Securities Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
13 Mar 24
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
1 Mar 24
Keros Therapeutics Q4 EPS $(1.34) Beats $(1.37) Estimate
28 Feb 24